|
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
RECRUITINGSponsored by Convergent Genomics, Inc.
Actively Recruiting
SponsorConvergent Genomics, Inc.
Started2019-10-15
Est. completion2034-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations21 sites
View on ClinicalTrials.gov →
NCT07673016
Summary
This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: GROUP 1: Bladder Cancer and/or Upper Tract UCC * Male or female ≥ 18 years of age who are scheduled for transurethral resection of bladder tumor (TURBT) and/or biopsy of urinary tract or * Patients on surveillance who are negative for recurrence or tumor at the time of study enrollment but have had previous urothelial cell carcinoma (UCC) or * Patients with muscle invasive bladder cancer (MIBC) or non-muscle invasive bladder cancer (NMIBC) scheduled for NAC and/or subsequent radical cystectomy (RC) * Able to provide consent prior to diagnostic TURBT, nephroureterectomy, or administration of NAC and/or RC * Able to provide at least 20cc urine. If patient cannot void sufficient volume of urine, urologist can pull urine from the bladder via catheter or cystoscope. Urine should not be collected immediately after resection * Participation in other bladder cancer studies is allowed. Experimental therapy must be documented in the case report forms GROUP 2: Hematuria Controls * Male or female ≥ 18 years of age presenting with gross or microscopic hematuria as defined by standard of care * No evidence of and/or history of bladder cancer, upper tract UCC, kidney cancer and/or prostate cancer at the time of collection * Able to provide consent * Able to provide at least 20cc urine * Participation in other studies is allowed. Experimental therapy must be documented in the case report forms Exclusion Criteria: GROUP 1: Bladder Cancer and/or Upper Tract UCC * Clinical, symptomatic urinary tract infection at time of initial urine collection * Unable to provide adequate urine sample GROUP 2: Hematuria Controls \- Evidence and/or History of bladder cancer, upper tract UCC, kidney cancer and/or prostate cancer at the time of collection
Conditions5
Bladder CancerCancerHematuriaUpper Tract Urothelial CancerUrothelial Carcinoma (UC)
Locations21 sites
Urology San Diego
Genesis Research, LLC
Urology Associates of Silicon Valley
UroPartners, LLC
Find trials near these locations
Cancer trials in San DiegoCancer trials in San JoseCancer trials in ChicagoCancer trials in Las VegasCancer trials in New YorkCancer trials in NashvilleCancer trials in AustinCancer trials in DallasCancer trials in San AntonioCancer trials in Virginia BeachAll trials in CaliforniaAll trials in IllinoisAll trials in MarylandAll trials in NevadaAll trials in New YorkAll trials in OhioAll trials in TennesseeAll trials in TexasAll trials in Virginia
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorConvergent Genomics, Inc.
Started2019-10-15
Est. completion2034-12
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations21 sites
View on ClinicalTrials.gov →
NCT07673016